The Biosensor/Interaction Analysis Core was formally established in 1997 to meet the growing need for macromolecular interaction analysis. Initial funding was partially provided by the Cancer Center, through both Core Grant Developmental Funds and non-Core Grant sources, as well as by the School of Medicine. Irwin Chaiken, PhD, Professor of Medicine, serves as Facility Director. Dr. Chaiken is a national expert in kinetic interaction analysis using biosensors as well as in the field of biomolecular recognition. Dr. Chaiken's laboratory was one of the first to apply the use of biosensory technology to specific macromolecular interaction systems. This biosensor work emerged from Dr. Chaiken's earlier work in the development of analytical affinity chromatography for interaction analysis using immobilized ligands. Dr, Chaiken planned and established the Biosensor/Interaction Analysis ore and now serves as it's Facility Director. The facility's Technical Director,. Gabriela Canziani, PhD, has more than ten years of experience in enzyme kinetics, structure-function of the catalytic sites of enzymes, and spectrophotometric methods, including fluorescence spectroscopy and biophysical analysis of lipid- protein interactions. Usage has increased steadily during this start-up period. The vast majority of users are repeat customers who are increasing their usage by both expanding the scope of current projects and initiating new projects. During the most recent budget year, 83% of usage was done by Cancer Center members and 79% was by Cancer Center members with peer- reviewed funding. Increased usage by Cancer Center members is very much anticipated for the next project period as this core becomes an NCI- approved Cancer Center Shared Resources and as more investigators become familiar with its growing capabilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-27
Application #
6573832
Study Section
Subcommittee G - Education (NCI)
Project Start
2001-12-01
Project End
2002-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
27
Fiscal Year
2002
Total Cost
$228,564
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Williams, Austin D; Reyes, Sylvia A; Arlow, Renee L et al. (2018) Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged Ann Surg Oncol 25:2875-2883
Anton, Lauren; Sierra, Luz-Jeannette; DeVine, Ann et al. (2018) Common Cervicovaginal Microbial Supernatants Alter Cervical Epithelial Function: Mechanisms by Which Lactobacillus crispatus Contributes to Cervical Health. Front Microbiol 9:2181
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bhagwat, Neha; Dulmage, Keely; Pletcher Jr, Charles H et al. (2018) An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Sci Rep 8:5035
Nair, Praful R; Alvey, Cory; Jin, Xiaoling et al. (2018) Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival. Bioconjug Chem 29:914-927
Kasner, Margaret T; Mick, Rosemarie; Jeschke, Grace R et al. (2018) Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs 36:657-666
Raposo-Ferreira, Talita M M; Brisson, Becky K; Durham, Amy C et al. (2018) Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas. Vet Pathol 55:622-633

Showing the most recent 10 out of 1047 publications